Do non-animal-derived antibodies have similar affinity and specificity to animal-derived ones? Do they work fine in all applications?

Non-animal-derived antibodies typically exhibit highly desirable characteristics such as being able to form a strong bond with targets (binding affinity), having a long shelf life (stability) and the ability to be very selective (specificity), usually outperforming animal-derived equivalents.

JRC scientist Marlies Halder, co-author of the EURL ECVAM Recommendation, states that “Animal-derived antibodies typically suffer from batch-to-batch variability and many show low specificity towards the target molecule. These problems can be easily solved through the use of non-animal-derived antibodies obtained by phage display technology. Their use will greatly improve reproducibility and relevance of scientific procedures and lead to more efficient and effective use of research funds.”

Poor reproducibility of experiments is bad news when it comes to time and money. In fact, it is estimated that many hundreds of millions of euro are inadvertently spent annually by the biomedical research community on non-specific and badly defined animal-derived antibodies. Moreover, significant losses are also being incurred as a consequence through associated waste of time and resources and the follow-up of potentially misleading research results.

Non-animal-derived antibodies can be reliably produced in unlimited amounts, which essentially ensures a life-time supply of antibodies with identical performance, a critical requirement for reproducibility of scientific experiments requiring affinity reagents.

Reference: https://ec.europa.eu/jrc/en/science-update/better-antibodies-without-using-animals#:~:text=Non%2Danimal%2Dderived%20antibodies%20typically,usually%20outperforming%20animal%2Dderived%20equivalents.